Arcus Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.27%
vs ±11.2% implied · ×0.20
shaded = implied · ▲▼ = realized
Arcus Biosciences has 4 disclosed suppliers and 4 disclosed customers in SEC filings.
Expected move
No implied move.
SentenceIf any of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead's internal manufacturing infrastructure for their optioned products, as appropriate, to deliver commercial supply.
SentenceWe have in-licensed rights to anti-PD-1 and CD39 antibodies from WuXi Biologics, and to domvanalimab from Abmuno.
RCUS 10-Kaccession 0001724521-26-000009
SentenceWith respect to zimberelimab, we agreed, as part of the WuXi PD-1 Agreement, that WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies until a certain number of years after marketing approval for zimberelimab, subject to certain exceptions.
RCUS 10-Kaccession 0001724521-26-000009
SentenceIn 2020, we and Gilead entered into the Gilead Collaboration Agreement, as amended, under which Gilead obtained an exclusive license to zimberelimab and time-limited exclusive options to all of our then-current and future programs during the collaboration term.
SentenceNon-operating income, net consists primarily of interest earned on our investments in fixed-income marketable securities, interest expense on the Hercules Agreement, and non-cash interest expense incurred under the effective interest method on our liability for sale of future royalties to BVF Partners L.P. ("BVF").
RCUS 10-Kaccession 0001724521-26-000009
SentenceFor each Taiho optioned program, Taiho is obligated to pay to us (i) an option exercise payment for each program that is between $3 million to $15 million, (ii) clinical, regulatory and commercialization milestones of up to $275 million except for casdatifan (the HIF-2α program) for which we may receive up to $317 million, and (iii) royalties on net sales in Taiho's territories ranging from high single digits to mid-teens.
RCUS 10-Kaccession 0001724521-26-000009
SentenceIn exchange, Taiho will make an option exercise payment to us along with milestone payments upon the achievement of clinical, regulatory and commercialization milestones, and, additionally pay royalties on net sales.
RCUS 10-Kaccession 0001724521-26-000009
Linked news
Arcus Biosciences, Inc.
18.19